Literature DB >> 29258331

Short Communication: Specimen Processing Impacts Tissue Tenofovir Pharmacokinetic Measurements.

Rahul P Bakshi1, Jennifer Breakey1, Madhuri Manohar1, Bhavna Jois1, Edward J Fuchs1, Mark A Marzinke1,2.   

Abstract

Antiretroviral drug concentrations at sites of HIV exposure are important drivers that influence the development of HIV pre-exposure chemoprophylaxis strategies and regimens. We assessed the effect of collection method-in the presence or absence of tissue culture medium-on tenofovir (TFV) and tenofovir diphosphate (TFV-DP) concentrations in colonic biopsies. We find significant baseline interbiopsy variation in TFV (38% CV) and TFV-DP (33% CV) concentrations. Incubation in medium leads to a fluid absorption-driven twofold increase in tissue weight with a concomitant 75% decrease in weight-adjusted tissue TFV concentrations 120 min post-incubation. In contrast, adjusted TFV-DP concentrations decrease by only 25% during the same period, with this difference not achieving statistical significance. Although colonic biopsies should be collected in the absence of medium for accurate TFV concentrations, the presence of medium does not significantly impact TFV-DP-dependent pharmacokinetic or pharmacodynamic assays. Appropriate assessment of tissue drug concentrations should account for biopsy collection method and drug mechanism of action.

Entities:  

Keywords:  PK/PD; antiretroviral; biopsy; tenofovir; tissue

Mesh:

Substances:

Year:  2018        PMID: 29258331      PMCID: PMC5899295          DOI: 10.1089/AID.2017.0231

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  3 in total

1.  Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066).

Authors:  Craig W Hendrix; Adriana Andrade; Namandjé N Bumpus; Angela D Kashuba; Mark A Marzinke; Ayana Moore; Peter L Anderson; Lane R Bushman; Edward J Fuchs; Ilene Wiggins; Christine Radebaugh; Heather A Prince; Rahul P Bakshi; Ruili Wang; Paul Richardson; Eugenie Shieh; Laura McKinstry; Xin Li; Deborah Donnell; Vanessa Elharrar; Kenneth H Mayer; Kristine B Patterson
Journal:  AIDS Res Hum Retroviruses       Date:  2015-10-15       Impact factor: 2.205

2.  Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicides.

Authors:  Patricia S Fletcher; Julie Elliott; Jean-Charles Grivel; Leonid Margolis; Peter Anton; Ian McGowan; Robin J Shattock
Journal:  AIDS       Date:  2006-06-12       Impact factor: 4.177

3.  HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention.

Authors:  Deborah Donnell; Jared M Baeten; Namandjé N Bumpus; Justin Brantley; David R Bangsberg; Jessica E Haberer; Andrew Mujugira; Nelly Mugo; Patrick Ndase; Craig Hendrix; Connie Celum
Journal:  J Acquir Immune Defic Syndr       Date:  2014-07-01       Impact factor: 3.731

  3 in total
  2 in total

1.  A Randomized, Open-Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel (the CHARM-03 Study).

Authors:  Ian M McGowan; Sylvain Chawki; Craig W Hendrix; Peter A Anton; Mark A Marzinke; Rhonda M Brand; Jarret C Engstrom; Lisa C Rohan; Kaleab Z Abebe; Nicola Richardson-Harman; Aaron Siegel; Alex Reinhart; John Steytler; Ronald Stall; Hans Spiegel; Beatrice Chen; Sharon L Achilles; Cindy E Jacobson; Elena Khanukova; Ross D Cranston
Journal:  AIDS Res Hum Retroviruses       Date:  2021-09-14       Impact factor: 1.723

2.  Higher colorectal tissue HIV infectivity in cisgender women compared with MSM before and during oral preexposure prophylaxis.

Authors:  Rogers Sekabira; Ian McGowan; Krista Yuhas; Rhonda M Brand; Mark A Marzinke; Yukari C Manabe; Ian Frank; Joseph Eron; Raphael J Landovitz; Peter Anton; Ross D Cranston; Peter Anderson; Kenneth H Mayer; K Rivet Amico; Timothy J Wilkin; Wairimu Chege; Adeodata R Kekitiinwa; Marybeth McCauley; Roy M Gulick; Craig W Hendrix
Journal:  AIDS       Date:  2021-08-01       Impact factor: 4.632

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.